Physician profile
Stephanie E Johnson
NPI 1952798019
$4,707.46
in general payments reported to CMS, 2019-2025
42 companies · $1,064 in 2025
The $1,064 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,654 · 2022: $282 · 2023: $745 · 2024: $962 · 2025: $1,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,771.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $478.24 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $470.17 | 2021-2025 | |
| Glaxosmithkline, LLC. | $417.79 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $334.61 | 2021-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $318.97 | 2021 | |
| Pfizer INC. | $274.91 | 2021-2025 | |
| Lilly USA, LLC | $255.46 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $177.14 | 2021 | |
| Dexcom, INC. | $166.41 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $139.02 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Antares Pharma, INC. | $137.86 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Sanofi-Aventis U.S. LLC | $121.47 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.49 | 2021-2024 | Jardiance |
| Ferring Pharmaceuticals INC. | $102.02 | 2024 | Adstiladrin |
| Astellas Pharma US INC | $97.98 | 2025 | Xtandi |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.